{
    "info": {
        "nct_id": "NCT05117931",
        "official_title": "Phase II Study of Amivantamab in EGFR or MET- Amplified Esophagogastric Cancer",
        "inclusion_criteria": "* Subject or legally authorized representative is willing and able to provide written informed consent.\n* Patients with previously treated metastatic or unresectable histologically-confirmed esophagogastric cancer who have received at least 1 line of therapy.\n* EGFR or MET amplification by tissue-NGS with copy number >8 and/or ctDNA amplification by any FDA and CLIA-approved assay\n* No prior receipt of an EGFR or MET inhibitor for esophagogastric cancer. (Note: if a patient previously received a EGFR inhibitor, but subsequently demonstrated a MET amplification, or previously received a MET inhibitor, but subsequently demonstrated an EGFR-amplification, inclusion is permitted).\n* Patients with HER2+ (IHC 3+ or IHC 2+/FISH+) tumors must have progressed on trastuzumab.\n* Measurable disease based on RECIST 1.1.\n* ≥ 18 years of age on day of signing informed consent.\n* Have an ECOG performance status of 0, 1, or 2.\n* Adequate organ function, defined as:\n\nA. Hemoglobin ≥9 g/dL\n\nB. ANC ≥1.0 x 10^9 /L\n\nC. Platelets ≥75 x 10^9 /L\n\nD. AST and ALT ≤3 x ULN (≤5 x ULN for subjects with liver metastases)\n\nE. Total bilirubin ≤1.5 x ULN; subjects with Gilbert's syndrome can enroll if conjugated bilirubin is within normal limits\n\nF. Serum creatinine <1.5 x ULN or if available, calculated or measured creatinine clearance >50 mL/min/1.73 m^2\n\n* Women of childbearing potential and male patients with women of childbearing potential partners must be willing to use an adequate method of contraception\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* Prior chemotherapy, targeted small molecule therapy, or biological therapy, within 2 weeks prior to study day 1 or who has not recovered (i.e., ≤ Grade 1 or at baseline) from adverse events due to a previously administered agent (excluding alopecia).\n* If subject received major surgery, they must have recovered adequately prior to starting therapy.\n* Known additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or in situ cervical cancer that has undergone potentially curative therapy.\n* Known active hepatitis B (e.g., HBsAg reactive or polymerase chain reaction detectable).\n\nNote: Subjects with a prior history of HBV demonstrated by positive hepatitis B core antibody are eligible if they have at Screening 1) a negative HBsAg and 2) a HBV DNA (viral load) below the lower limit of quantification, per local testing. Subjects with a positive HBsAg due to recent vaccination are eligible if HBV DNA (viral load) is below the lower limit of quantification, per local testing.\n\n* Known active hepatitis C (e.g., HCV RNA [qualitative] is detected).\n\nNote: Subjects with a prior history of HCV, who have completed antiviral treatment and have subsequently documented HCV RNA below the lower limit of quantification per local testing are eligible.\n\n* Other clinically active or chronic liver disease.\n* Subject has uncontrolled inter-current illness, including but not limited to poorly controlled diabetes, ongoing or active infection (i.e., has discontinued all antibiotics for at least one week prior to first dose of study drug), or psychiatric illness/social situation that would limit compliance with study requirements. Subjects with medical conditions requiring chronic continuous oxygen therapy are excluded.\n* Pulmonary embolism (PE) and deep vein thrombosis (DVT), within 1 month of start of study drug.\n* Myocardial infarction, unstable angina, stroke, transient ischemic attach (TIA), or coronary/peripheral artery bypass graft, or any acute coronary syndrome within 6 months of start of study drug.\n* Congestive heart failure defined as New York Heart Association (NYHA) Class III-IV or hospitalization for congestive heart failure (any NYHA class) within 6 months of start of study drug.\n* Interstitial lung disease (ILD), including drug-induced ILD or radiation pneumonitis requiring treatment with prolonged steroids or other immune suppressive agents that is unresolved or resolved within the last 3 months.\n* Immune-mediated rash from checkpoint inhibitors that has not resolved prior to enrollment.\n* Known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial, in the opinion of the treating investigator.\n* Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the pre-screening or screening visit through 6 months after the last dose of trial treatment.\n* Prisoners, or subjects who are compulsory detained.",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* Adequate organ function, defined as:",
            "criterions": [
                {
                    "exact_snippets": "Adequate organ function",
                    "criterion": "organ function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with HER2+ (IHC 3+ or IHC 2+/FISH+) tumors must have progressed on trastuzumab.",
            "criterions": [
                {
                    "exact_snippets": "HER2+ (IHC 3+ or IHC 2+/FISH+) tumors",
                    "criterion": "HER2 status",
                    "requirements": [
                        {
                            "requirement_type": "expression",
                            "expected_value": [
                                "IHC 3+",
                                "IHC 2+/FISH+"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "must have progressed on trastuzumab",
                    "criterion": "progression on trastuzumab",
                    "requirements": [
                        {
                            "requirement_type": "progression",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* No prior receipt of an EGFR or MET inhibitor for esophagogastric cancer. (Note: if a patient previously received a EGFR inhibitor, but subsequently demonstrated a MET amplification, or previously received a MET inhibitor, but subsequently demonstrated an EGFR-amplification, inclusion is permitted).",
            "criterions": [
                {
                    "exact_snippets": "No prior receipt of an EGFR or MET inhibitor for esophagogastric cancer.",
                    "criterion": "prior receipt of EGFR or MET inhibitor for esophagogastric cancer",
                    "requirements": [
                        {
                            "requirement_type": "history of receipt",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "if a patient previously received a EGFR inhibitor, but subsequently demonstrated a MET amplification, or previously received a MET inhibitor, but subsequently demonstrated an EGFR-amplification, inclusion is permitted",
                    "criterion": "subsequent demonstration of MET or EGFR amplification after prior inhibitor",
                    "requirements": [
                        {
                            "requirement_type": "sequence of events",
                            "expected_value": "prior EGFR inhibitor and subsequent MET amplification OR prior MET inhibitor and subsequent EGFR amplification"
                        }
                    ]
                }
            ]
        },
        {
            "line": "B. ANC ≥1.0 x 10^9 /L",
            "criterions": [
                {
                    "exact_snippets": "ANC ≥1.0 x 10^9 /L",
                    "criterion": "absolute neutrophil count (ANC)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1.0,
                                "unit": "x 10^9 /L"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Women of childbearing potential and male patients with women of childbearing potential partners must be willing to use an adequate method of contraception",
            "criterions": [
                {
                    "exact_snippets": "Women of childbearing potential ... must be willing to use an adequate method of contraception",
                    "criterion": "contraception use (women of childbearing potential)",
                    "requirements": [
                        {
                            "requirement_type": "willingness to use contraception",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "adequacy of contraception method",
                            "expected_value": "adequate"
                        }
                    ]
                },
                {
                    "exact_snippets": "male patients with women of childbearing potential partners must be willing to use an adequate method of contraception",
                    "criterion": "contraception use (male patients with women of childbearing potential partners)",
                    "requirements": [
                        {
                            "requirement_type": "willingness to use contraception",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "adequacy of contraception method",
                            "expected_value": "adequate"
                        }
                    ]
                }
            ]
        },
        {
            "line": "F. Serum creatinine <1.5 x ULN or if available, calculated or measured creatinine clearance >50 mL/min/1.73 m^2",
            "criterions": [
                {
                    "exact_snippets": "Serum creatinine <1.5 x ULN",
                    "criterion": "serum creatinine",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 1.5,
                                "unit": "x ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "calculated or measured creatinine clearance >50 mL/min/1.73 m^2",
                    "criterion": "creatinine clearance",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 50,
                                "unit": "mL/min/1.73 m^2"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* EGFR or MET amplification by tissue-NGS with copy number >8 and/or ctDNA amplification by any FDA and CLIA-approved assay",
            "criterions": [
                {
                    "exact_snippets": "EGFR or MET amplification by tissue-NGS with copy number >8",
                    "criterion": "EGFR amplification (tissue-NGS)",
                    "requirements": [
                        {
                            "requirement_type": "amplification",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "copy number",
                            "expected_value": {
                                "operator": ">",
                                "value": 8,
                                "unit": "N/A"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "EGFR or MET amplification by tissue-NGS with copy number >8",
                    "criterion": "MET amplification (tissue-NGS)",
                    "requirements": [
                        {
                            "requirement_type": "amplification",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "copy number",
                            "expected_value": {
                                "operator": ">",
                                "value": 8,
                                "unit": "N/A"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "ctDNA amplification by any FDA and CLIA-approved assay",
                    "criterion": "ctDNA amplification (FDA and CLIA-approved assay)",
                    "requirements": [
                        {
                            "requirement_type": "amplification",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Have an ECOG performance status of 0, 1, or 2.",
            "criterions": [
                {
                    "exact_snippets": "ECOG performance status of 0, 1, or 2",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 2,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* ≥ 18 years of age on day of signing informed consent.",
            "criterions": [
                {
                    "exact_snippets": "≥ 18 years of age",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "age",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "D. AST and ALT ≤3 x ULN (≤5 x ULN for subjects with liver metastases)",
            "criterions": [
                {
                    "exact_snippets": "AST and ALT ≤3 x ULN (≤5 x ULN for subjects with liver metastases)",
                    "criterion": "AST level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 3,
                                        "unit": "x ULN"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "AST and ALT ≤3 x ULN (≤5 x ULN for subjects with liver metastases)",
                    "criterion": "ALT level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 3,
                                        "unit": "x ULN"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "≤5 x ULN for subjects with liver metastases",
                    "criterion": "AST level in subjects with liver metastases",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 5,
                                        "unit": "x ULN"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "≤5 x ULN for subjects with liver metastases",
                    "criterion": "ALT level in subjects with liver metastases",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 5,
                                        "unit": "x ULN"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "A. Hemoglobin ≥9 g/dL",
            "criterions": [
                {
                    "exact_snippets": "Hemoglobin ≥9 g/dL",
                    "criterion": "hemoglobin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 9,
                                "unit": "g/dL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with previously treated metastatic or unresectable histologically-confirmed esophagogastric cancer who have received at least 1 line of therapy.",
            "criterions": [
                {
                    "exact_snippets": "previously treated metastatic or unresectable histologically-confirmed esophagogastric cancer",
                    "criterion": "esophagogastric cancer",
                    "requirements": [
                        {
                            "requirement_type": "histological confirmation",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "disease status",
                            "expected_value": [
                                "metastatic",
                                "unresectable"
                            ]
                        },
                        {
                            "requirement_type": "prior treatment",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "have received at least 1 line of therapy",
                    "criterion": "lines of prior therapy",
                    "requirements": [
                        {
                            "requirement_type": "number of lines",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "lines"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "E. Total bilirubin ≤1.5 x ULN; subjects with Gilbert's syndrome can enroll if conjugated bilirubin is within normal limits",
            "criterions": [
                {
                    "exact_snippets": "Total bilirubin ≤1.5 x ULN",
                    "criterion": "total bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "x ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "subjects with Gilbert's syndrome can enroll if conjugated bilirubin is within normal limits",
                    "criterion": "conjugated bilirubin in subjects with Gilbert's syndrome",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": "within normal limits"
                        }
                    ]
                }
            ]
        },
        {
            "line": "C. Platelets ≥75 x 10^9 /L",
            "criterions": [
                {
                    "exact_snippets": "Platelets ≥75 x 10^9 /L",
                    "criterion": "platelet count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 75,
                                "unit": "x 10^9 /L"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Subject or legally authorized representative is willing and able to provide written informed consent.",
            "criterions": [
                {
                    "exact_snippets": "Subject or legally authorized representative is willing and able to provide written informed consent.",
                    "criterion": "informed consent",
                    "requirements": [
                        {
                            "requirement_type": "willingness to provide",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "ability to provide",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "form",
                            "expected_value": "written"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Measurable disease based on RECIST 1.1.",
            "criterions": [
                {
                    "exact_snippets": "Measurable disease based on RECIST 1.1.",
                    "criterion": "disease",
                    "requirements": [
                        {
                            "requirement_type": "measurability",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "assessment_criteria",
                            "expected_value": "RECIST 1.1"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Interstitial lung disease (ILD), including drug-induced ILD or radiation pneumonitis requiring treatment with prolonged steroids or other immune suppressive agents that is unresolved or resolved within the last 3 months.",
            "criterions": [
                {
                    "exact_snippets": "Interstitial lung disease (ILD)",
                    "criterion": "interstitial lung disease (ILD)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "drug-induced ILD",
                    "criterion": "drug-induced interstitial lung disease (ILD)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "radiation pneumonitis requiring treatment with prolonged steroids or other immune suppressive agents",
                    "criterion": "radiation pneumonitis requiring treatment",
                    "requirements": [
                        {
                            "requirement_type": "treatment type",
                            "expected_value": [
                                "prolonged steroids",
                                "other immune suppressive agents"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "that is unresolved or resolved within the last 3 months",
                    "criterion": "interstitial lung disease (ILD) or radiation pneumonitis status",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": [
                                "unresolved",
                                "resolved within the last 3 months"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or in situ cervical cancer that has undergone potentially curative therapy.",
            "criterions": [
                {
                    "exact_snippets": "Known additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or in situ cervical cancer that has undergone potentially curative therapy.",
                    "criterion": "additional malignancy",
                    "requirements": [
                        {
                            "requirement_type": "progression",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "active treatment requirement",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "exception diagnoses",
                            "expected_value": [
                                "basal cell carcinoma of the skin",
                                "squamous cell carcinoma of the skin",
                                "in situ cervical cancer that has undergone potentially curative therapy"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "Note: Subjects with a prior history of HCV, who have completed antiviral treatment and have subsequently documented HCV RNA below the lower limit of quantification per local testing are eligible.",
            "criterions": [
                {
                    "exact_snippets": "prior history of HCV",
                    "criterion": "history of HCV infection",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "have completed antiviral treatment",
                    "criterion": "completion of antiviral treatment for HCV",
                    "requirements": [
                        {
                            "requirement_type": "completion",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "documented HCV RNA below the lower limit of quantification per local testing",
                    "criterion": "HCV RNA level",
                    "requirements": [
                        {
                            "requirement_type": "quantification",
                            "expected_value": {
                                "operator": "<",
                                "value": 0,
                                "unit": "lower limit of quantification (per local testing)"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Other clinically active or chronic liver disease.",
            "criterions": [
                {
                    "exact_snippets": "Other clinically active or chronic liver disease",
                    "criterion": "liver disease",
                    "requirements": [
                        {
                            "requirement_type": "activity status",
                            "expected_value": [
                                "clinically active",
                                "chronic"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "Note: Subjects with a prior history of HBV demonstrated by positive hepatitis B core antibody are eligible if they have at Screening 1) a negative HBsAg and 2) a HBV DNA (viral load) below the lower limit of quantification, per local testing. Subjects with a positive HBsAg due to recent vaccination are eligible if HBV DNA (viral load) is below the lower limit of quantification, per local testing.",
            "criterions": [
                {
                    "exact_snippets": "prior history of HBV demonstrated by positive hepatitis B core antibody",
                    "criterion": "prior history of HBV",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "hepatitis B core antibody",
                            "expected_value": "positive"
                        }
                    ]
                },
                {
                    "exact_snippets": "at Screening 1) a negative HBsAg",
                    "criterion": "HBsAg at Screening",
                    "requirements": [
                        {
                            "requirement_type": "HBsAg",
                            "expected_value": "negative"
                        }
                    ]
                },
                {
                    "exact_snippets": "at Screening ... 2) a HBV DNA (viral load) below the lower limit of quantification, per local testing",
                    "criterion": "HBV DNA (viral load) at Screening",
                    "requirements": [
                        {
                            "requirement_type": "viral load",
                            "expected_value": {
                                "operator": "<",
                                "value": 1,
                                "unit": "lower limit of quantification"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "positive HBsAg due to recent vaccination ... HBV DNA (viral load) is below the lower limit of quantification, per local testing",
                    "criterion": "HBsAg due to recent vaccination and HBV DNA (viral load)",
                    "requirements": [
                        {
                            "requirement_type": "HBsAg",
                            "expected_value": "positive"
                        },
                        {
                            "requirement_type": "cause of HBsAg positivity",
                            "expected_value": "recent vaccination"
                        },
                        {
                            "requirement_type": "viral load",
                            "expected_value": {
                                "operator": "<",
                                "value": 1,
                                "unit": "lower limit of quantification"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known active hepatitis C (e.g., HCV RNA [qualitative] is detected).",
            "criterions": [
                {
                    "exact_snippets": "Known active hepatitis C",
                    "criterion": "active hepatitis C infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "HCV RNA [qualitative] is detected",
                    "criterion": "HCV RNA (qualitative)",
                    "requirements": [
                        {
                            "requirement_type": "detectability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Pulmonary embolism (PE) and deep vein thrombosis (DVT), within 1 month of start of study drug.",
            "criterions": [
                {
                    "exact_snippets": "Pulmonary embolism (PE) ... within 1 month of start of study drug",
                    "criterion": "pulmonary embolism (PE)",
                    "requirements": [
                        {
                            "requirement_type": "occurrence_time_from_study_drug_start",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "month"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "deep vein thrombosis (DVT), within 1 month of start of study drug",
                    "criterion": "deep vein thrombosis (DVT)",
                    "requirements": [
                        {
                            "requirement_type": "occurrence_time_from_study_drug_start",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "month"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the pre-screening or screening visit through 6 months after the last dose of trial treatment.",
            "criterions": [
                {
                    "exact_snippets": "Is pregnant",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "breastfeeding",
                    "criterion": "breastfeeding status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "expecting to conceive ... within the projected duration of the trial, starting with the pre-screening or screening visit through 6 months after the last dose of trial treatment",
                    "criterion": "expectation to conceive children during trial period",
                    "requirements": [
                        {
                            "requirement_type": "expectation to conceive",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "expecting to ... father children within the projected duration of the trial, starting with the pre-screening or screening visit through 6 months after the last dose of trial treatment",
                    "criterion": "expectation to father children during trial period",
                    "requirements": [
                        {
                            "requirement_type": "expectation to father children",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Myocardial infarction, unstable angina, stroke, transient ischemic attach (TIA), or coronary/peripheral artery bypass graft, or any acute coronary syndrome within 6 months of start of study drug.",
            "criterions": [
                {
                    "exact_snippets": "Myocardial infarction ... within 6 months of start of study drug",
                    "criterion": "myocardial infarction",
                    "requirements": [
                        {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": ">=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "unstable angina ... within 6 months of start of study drug",
                    "criterion": "unstable angina",
                    "requirements": [
                        {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": ">=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "stroke ... within 6 months of start of study drug",
                    "criterion": "stroke",
                    "requirements": [
                        {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": ">=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "transient ischemic attach (TIA) ... within 6 months of start of study drug",
                    "criterion": "transient ischemic attack (TIA)",
                    "requirements": [
                        {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": ">=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "coronary/peripheral artery bypass graft ... within 6 months of start of study drug",
                    "criterion": "coronary or peripheral artery bypass graft",
                    "requirements": [
                        {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": ">=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "any acute coronary syndrome within 6 months of start of study drug",
                    "criterion": "acute coronary syndrome",
                    "requirements": [
                        {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": ">=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prisoners, or subjects who are compulsory detained.",
            "criterions": [
                {
                    "exact_snippets": "Prisoners",
                    "criterion": "prisoner status",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "subjects who are compulsory detained",
                    "criterion": "compulsory detention status",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Congestive heart failure defined as New York Heart Association (NYHA) Class III-IV or hospitalization for congestive heart failure (any NYHA class) within 6 months of start of study drug.",
            "criterions": [
                {
                    "exact_snippets": "Congestive heart failure defined as New York Heart Association (NYHA) Class III-IV",
                    "criterion": "congestive heart failure",
                    "requirements": [
                        {
                            "requirement_type": "NYHA class",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "N/A"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "hospitalization for congestive heart failure (any NYHA class) within 6 months of start of study drug",
                    "criterion": "hospitalization for congestive heart failure",
                    "requirements": [
                        {
                            "requirement_type": "time since hospitalization",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial, in the opinion of the treating investigator.",
            "criterions": [
                {
                    "exact_snippets": "Known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial, in the opinion of the treating investigator.",
                    "criterion": "psychiatric or substance abuse disorders",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "impact on cooperation with trial requirements",
                            "expected_value": "would interfere"
                        },
                        {
                            "requirement_type": "investigator judgment",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Immune-mediated rash from checkpoint inhibitors that has not resolved prior to enrollment.",
            "criterions": [
                {
                    "exact_snippets": "Immune-mediated rash from checkpoint inhibitors that has not resolved prior to enrollment",
                    "criterion": "immune-mediated rash from checkpoint inhibitors",
                    "requirements": [
                        {
                            "requirement_type": "resolution status",
                            "expected_value": "not resolved prior to enrollment"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* If subject received major surgery, they must have recovered adequately prior to starting therapy.",
            "criterions": [
                {
                    "exact_snippets": "If subject received major surgery",
                    "criterion": "major surgery",
                    "requirements": [
                        {
                            "requirement_type": "history of major surgery",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "they must have recovered adequately prior to starting therapy",
                    "criterion": "recovery from major surgery",
                    "requirements": [
                        {
                            "requirement_type": "recovery status",
                            "expected_value": "adequate"
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "prior to starting therapy"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known active hepatitis B (e.g., HBsAg reactive or polymerase chain reaction detectable).",
            "criterions": [
                {
                    "exact_snippets": "Known active hepatitis B",
                    "criterion": "hepatitis B infection",
                    "requirements": [
                        {
                            "requirement_type": "activity status",
                            "expected_value": "active"
                        },
                        {
                            "requirement_type": "knowledge status",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "HBsAg reactive",
                    "criterion": "hepatitis B surface antigen (HBsAg)",
                    "requirements": [
                        {
                            "requirement_type": "reactivity",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "polymerase chain reaction detectable",
                    "criterion": "hepatitis B viral DNA (PCR)",
                    "requirements": [
                        {
                            "requirement_type": "detectability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Subject has uncontrolled inter-current illness, including but not limited to poorly controlled diabetes, ongoing or active infection (i.e., has discontinued all antibiotics for at least one week prior to first dose of study drug), or psychiatric illness/social situation that would limit compliance with study requirements. Subjects with medical conditions requiring chronic continuous oxygen therapy are excluded.",
            "criterions": [
                {
                    "exact_snippets": "uncontrolled inter-current illness",
                    "criterion": "inter-current illness",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    ]
                },
                {
                    "exact_snippets": "poorly controlled diabetes",
                    "criterion": "diabetes",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "poorly controlled"
                        }
                    ]
                },
                {
                    "exact_snippets": "ongoing or active infection (i.e., has discontinued all antibiotics for at least one week prior to first dose of study drug)",
                    "criterion": "infection",
                    "requirements": [
                        {
                            "requirement_type": "activity status",
                            "expected_value": "ongoing or active"
                        },
                        {
                            "requirement_type": "antibiotic discontinuation duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "week"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "psychiatric illness/social situation that would limit compliance with study requirements",
                    "criterion": "psychiatric illness or social situation",
                    "requirements": [
                        {
                            "requirement_type": "impact on compliance",
                            "expected_value": "would limit compliance with study requirements"
                        }
                    ]
                },
                {
                    "exact_snippets": "medical conditions requiring chronic continuous oxygen therapy",
                    "criterion": "medical conditions requiring chronic continuous oxygen therapy",
                    "requirements": [
                        {
                            "requirement_type": "requirement for chronic continuous oxygen therapy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior chemotherapy, targeted small molecule therapy, or biological therapy, within 2 weeks prior to study day 1 or who has not recovered (i.e., ≤ Grade 1 or at baseline) from adverse events due to a previously administered agent (excluding alopecia).",
            "criterions": [
                {
                    "exact_snippets": "Prior chemotherapy, targeted small molecule therapy, or biological therapy, within 2 weeks prior to study day 1",
                    "criterion": "prior chemotherapy, targeted small molecule therapy, or biological therapy",
                    "requirements": [
                        {
                            "requirement_type": "time since last administration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "who has not recovered (i.e., ≤ Grade 1 or at baseline) from adverse events due to a previously administered agent (excluding alopecia)",
                    "criterion": "recovery from adverse events due to previously administered agent (excluding alopecia)",
                    "requirements": [
                        {
                            "requirement_type": "severity of adverse events",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "Grade"
                            }
                        },
                        {
                            "requirement_type": "recovery to baseline",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}